171 related articles for article (PubMed ID: 35585597)
1. Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.
Zou J; Wang S; Chai N; Yue H; Ye P; Guo P; Li F; Wei B; Ma G; Wei W; Linghu E
J Nanobiotechnology; 2022 May; 20(1):233. PubMed ID: 35585597
[TBL] [Abstract][Full Text] [Related]
2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
3. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
Yoon C; Lu J; Kim BJ; Cho SJ; Kim JH; Moy RH; Ryeom SW; Yoon SS
J Gastrointest Surg; 2023 Apr; 27(4):666-676. PubMed ID: 36627466
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S
Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042
[TBL] [Abstract][Full Text] [Related]
8. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
9. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
11. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
13. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
Anticancer Res; 2016 Dec; 36(12):6699-6703. PubMed ID: 27920005
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.
Zhou N; Wang W; Xu C; Yu W
Pathol Res Pract; 2021 Aug; 224():153487. PubMed ID: 34225215
[TBL] [Abstract][Full Text] [Related]
18. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
Liu YY; Zhang LY; Du WZ
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effect of paclitaxel for gastric cancer is AUC dependent].
Yamada T; Tanaka N; Furukawa K; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Katsuta M; Ohaki Y; Tajiri T
Gan To Kagaku Ryoho; 2008 Feb; 35(2):251-3. PubMed ID: 18281760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
